In clinical trials, biochemical markers provide useful information on the drug's mode of
action, therapeutic response and side effect monitoring and can act as surrogate endpoints …

Purpose Sarcopenia is an age-related muscle condition which is frequently a precursor of
frailty, mobility disability and premature death. It has a high prevalence in older populations …

Sarcopenia, the age-related skeletal muscle decline, is associated with relevant clinical and
socioeconomic negative outcomes in older persons. The study of this phenomenon and the …

Background In 2016, an expert working group was convened under the auspices of the
European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis …

Introduction: Sarcopenia, the age-related loss of skeletal muscle mass and function, is a
global health problem that contributes to the development of physical disability, morbidity …

The term “sarcopenia” describes the progressive decline of muscle mass, strength and
function occurring with aging. It is not considered a disease, but the direct consequence of …

Sarcopenia is a complex multifactorial condition that can by treated with multimodal
approaches. No pharmacologic agent to prevent or treat sarcopenia has proven to be as …

Sarcopenia, the loss of skeletal muscle mass and function with age, was first recognized as
a disease in the International Classification of Diseases, Tenth Revision, Clinical …

Background Sarcopenia, defined as the pathological decline in muscle mass, muscle
strength and physical performance with aging, has become one of the geriatric giants …

Loss of physical function in older adults may be, at least in part, explained by sarcopenia, a
phenomenon characterized by a reduction in number and size of muscle fibres and by …